Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.215 USD | -5.93% | -2.82% | -17.26% |
04:29pm | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
06-04 | FDA panel to review psychedelic drug MDMA for first time | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.26% | 524M | |
+54.18% | 55.7B | |
+41.08% | 39.91B | |
-5.67% | 39.57B | |
-5.56% | 28.16B | |
+15.94% | 26.3B | |
-21.34% | 18.94B | |
+32.74% | 12.17B | |
+26.58% | 12.12B | |
+2.58% | 12.12B |
- Stock Market
- Equities
- CMPS Stock
- News COMPASS Pathways plc
- Transcript : COMPASS Pathways plc, Q3 2021 Earnings Call, Nov 09, 2021